Mind Medicine (MindMed) Inc. (MNMD): Price and Financial Metrics

Mind Medicine (MindMed) Inc. (MNMD): $0.87

0.08 (+9.48%)

POWR Rating

Component Grades













Add MNMD to Watchlist
Sign Up

Industry: Biotech



in industry

MNMD Stock Price Chart Interactive Chart >

Price chart for MNMD

MNMD Price/Volume Stats

Current price $0.87 52-week high $4.04
Prev. close $0.80 52-week low $0.70
Day low $0.80 Volume 1,950,900
Day high $0.87 Avg. volume 3,711,787
50-day MA $0.93 Dividend yield N/A
200-day MA $1.66 Market Cap 368.47M

Mind Medicine (MindMed) Inc. (MNMD) Company Bio

Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.

MNMD Latest News Stream

Event/Time News Detail
Loading, please wait...

MNMD Latest Social Stream

Loading social stream, please wait...

View Full MNMD Social Stream

Latest MNMD News From Around the Web

Below are the latest news stories about Mind Medicine (MindMed) Inc that investors may wish to consider to help them evaluate MNMD as an investment opportunity.

MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, announced today that all the Company's issued and outstanding multiple voting shares (the "Multiple Voting Shares") will undergo a mandatory conversion into subordinate voting shares (the "Subordinate Voting Shares") (the "Conversion"), in accordance with the Company's Articles. The Co

Yahoo | February 23, 2022

Psychedelic Stock Gainers And Losers From February 15, 2022 | Benzinga

GAINERS: Mind Medicine (NASDAQ:

Benzinga | February 15, 2022

Why Shares of Mind Medicine Jumped 13.4% on Wednesday

The clinical-stage biopharmaceutical company benefited from an increased interest in companies working on psychedelic therapies.

The Motley Fool | February 9, 2022

FDA Greenlight Sets the Stage for Upside With Mind Medicine

Few catalysts can move healthcare stocks like a regulatory clearance can - and MNMD stock could be 2022's top psychedelics-sector investment.

David Moadel on InvestorPlace | February 8, 2022

Thinking about buying stock in Velodyne Lidar, Chegg, Louisiana-Pacific Corp, Harley-Davidson, or Mind Medicine?

NEW YORK , Feb. 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VLDR, CHGG, LPX, HOG, and MNMD. … Full story available on Benzinga.com

Benzinga | February 8, 2022

Read More 'MNMD' Stories Here

MNMD Price Returns

1-mo 3.87%
3-mo -28.69%
6-mo -55.84%
1-year -74.41%
3-year N/A
5-year N/A
YTD -36.96%
2021 -54.75%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5513 seconds.